Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

"Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment".

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2018 Sep 18. pii: S0304-3835(18)30580-9. doi: 10.1016/j.canlet.2018.09.023. [Epub ahead of print]

PMID:
30240588
2.

Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4.

Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL; Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM.

Mol Oncol. 2018 Sep;12(9):1540-1558. doi: 10.1002/1878-0261.12319. Epub 2018 Aug 9.

3.

Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions.

Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R.

Biochimie. 2017 Aug;139:27-37. doi: 10.1016/j.biochi.2017.05.009. Epub 2017 May 17.

PMID:
28528272
4.

The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse.

Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE.

PLoS One. 2016 Dec 21;11(12):e0167754. doi: 10.1371/journal.pone.0167754. eCollection 2016.

5.

Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.

Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A.

Nature. 2016 Sep 22;537(7621):548-552. doi: 10.1038/nature19360. Epub 2016 Sep 14.

PMID:
27626377
6.

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L.

Oncotarget. 2016 Apr 12;7(15):19997-20015. doi: 10.18632/oncotarget.7671.

7.

Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells.

Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K.

Data Brief. 2015 Sep 30;5:468-75. doi: 10.1016/j.dib.2015.09.022. eCollection 2015 Dec.

8.

Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM.

Clin Exp Metastasis. 2015 Dec;32(8):755-67. doi: 10.1007/s10585-015-9742-1. Epub 2015 Sep 9.

PMID:
26349943
9.

Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells.

Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K.

Biochimie. 2016 Mar;122:208-18. doi: 10.1016/j.biochi.2015.09.003. Epub 2015 Sep 3.

10.

High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K.

Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11.

PMID:
25466510
11.

Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Brix K, McInnes J, Al-Hashimi A, Rehders M, Tamhane T, Haugen MH.

Protoplasma. 2015 May;252(3):755-74. doi: 10.1007/s00709-014-0730-0. Epub 2014 Nov 16. Review.

PMID:
25398648
12.

Nuclear legumain activity in colorectal cancer.

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM.

PLoS One. 2013;8(1):e52980. doi: 10.1371/journal.pone.0052980. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/05c95441-890f-4707-a1bc-c4d386561191.

13.

Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M.

Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R.

Biochimie. 2012 Dec;94(12):2590-9. doi: 10.1016/j.biochi.2012.07.026. Epub 2012 Aug 10.

PMID:
22902879
14.

Comment on the Importance of S100A4 in regulation of MMP-13.

Berge G, Andersen K, Haugen MH, Maelandsmo GM.

J Biol Chem. 2010 Dec 31;285(53):le23; author reply le24. doi: 10.1074/jbc.L110.125898. No abstract available.

15.

TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins.

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T.

Tumour Biol. 2011 Feb;32(1):1-12. doi: 10.1007/s13277-010-0073-1. Epub 2010 Jul 24.

PMID:
20652782
16.

Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R.

BMC Cancer. 2010 Jan 15;10:17. doi: 10.1186/1471-2407-10-17.

17.

The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications.

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM.

BMC Cancer. 2008 Jun 13;8:172. doi: 10.1186/1471-2407-8-172.

Supplemental Content

Loading ...
Support Center